Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBN-101 in Diabetic Foot Infection
NCT02723539Phase 1Completed
- Sponsor
- Microbion
- Start
- Mar 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pravibismane in diabetic foot infection (DFI) (4 arms), sponsored by Microbion. Primary endpoints: Proportion of participants with treatment-related adverse events and Proportion of participants who are clinically cured. Started Mar 2017; status: completed.
02
Drugs
pravibismane
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on NCT02723539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723539.